Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006:2006:24502.
doi: 10.1155/PPAR/2006/24502.

Diabetes, TZDs, and Bone: A Review of the Clinical Evidence

Ann V Schwartz  1
Affiliations

Diabetes, TZDs, and Bone: A Review of the Clinical Evidence

Ann V Schwartz. PPAR Res. 2006.

Abstract

Evidence from rodent and in vitro models suggests that activation of PPAR-gamma by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether PPAR-gamma activation also impacts bone in humans. In addition, since type 2 diabetes is associated with higher fracture risk, an understanding of the clinical impact of TZDs on bone is needed to guide fracture prevention efforts in this population. This review summarizes current findings regarding type 2 diabetes and increased fracture risk and then considers the available evidence regarding TZD use and bone metabolism in humans.

PubMed Disclaimer

References

    1. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401–406. - PMC - PubMed
    1. Sorocéanu MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. Journal of Endocrinology. 2004;183(1):203–216. - PubMed
    1. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone) Calcified Tissue International. 2004;75(4):329–337. - PubMed
    1. Jennermann C, Triantafillou J, Cowan D, Pennink B, Connolly K, Morris D. Effects of thiazolidinediones on bone turnover in the rat. Journal of Bone and Mineral Research. 1995;10:S241. (Abstract S361).
    1. Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcified Tissue International. 2001;69(1):46–50. - PubMed

LinkOut - more resources